| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| X Wang, C M Cahill, M A Piñeyro, J Zhou, M E Doyle, J M Ega. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Endocrinology. vol 140. issue 10. 1999-10-12. PMID:10499550. |
the results of electrophoretic mobility shift experiments showed that pdx-1 protein binding to the al element of the rat insulin ii promoter was also increased 2 h post treatment with glp-1. |
1999-10-12 |
2023-08-12 |
rat |
| A M Salapatek, P E MacDonald, H Y Gaisano, M B Wheele. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells. Molecular endocrinology (Baltimore, Md.). vol 13. issue 8. 1999-09-20. PMID:10446905. |
mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (glp-1) receptor can functionally uncouple glp-1-stimulated insulin secretion in hit-t15 cells. |
1999-09-20 |
2023-08-12 |
rat |
| A M Salapatek, P E MacDonald, H Y Gaisano, M B Wheele. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells. Molecular endocrinology (Baltimore, Md.). vol 13. issue 8. 1999-09-20. PMID:10446905. |
prolonged exposure to glp-1 (10 nm, 17 h), not only led to an increase in insulin secretion but also increased insulin mrna levels, but only in cells expressing the wt-glp-1 r and not the mutant isoforms. |
1999-09-20 |
2023-08-12 |
rat |
| A M Salapatek, P E MacDonald, H Y Gaisano, M B Wheele. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells. Molecular endocrinology (Baltimore, Md.). vol 13. issue 8. 1999-09-20. PMID:10446905. |
these studies demonstrate that the glp-1 receptor efficiently couples to ac to stimulate insulin secretion and that receptors lacking critical residues in the proximal region of the third intracellular loop can effectively uncouple the receptor from camp production, vdcc activity, insulin secretion, and insulin biosynthesis. |
1999-09-20 |
2023-08-12 |
rat |
| M D Robertson, G Livesey, L M Morgan, S M Hampton, J C Mather. The influence of the colon on postprandial glucagon-like peptide 1 (7-36) amide concentration in man. The Journal of endocrinology. vol 161. issue 1. 1999-09-01. PMID:10194525. |
circulating levels of glucose, insulin, glucagon, glucose insulinotrophic peptide (gip) and glp-1 were measured over a 9-h postprandial period. |
1999-09-01 |
2023-08-12 |
human |
| N N'Diaye, P Hamet, J Tremblay, J M Boutin, L Gaboury, A Lacroi. Asynchronous development of bilateral nodular adrenal hyperplasia in gastric inhibitory polypeptide-dependent cushing's syndrome. The Journal of clinical endocrinology and metabolism. vol 84. issue 8. 1999-08-19. PMID:10443649. |
plasma cortisol and gip levels were positively correlated (r = 0.95; p = 0.0001); cortisol was stimulated by the administration of human gip iv (225%), but not by glp-1, insulin, trh, gnrh, glucagon, arginine vasopressin, upright posture, or cisapride orally. |
1999-08-19 |
2023-08-12 |
human |
| E G Siegel, G Scharf, B Gallwitz, R Mentlein, C Morys-Wortmann, U R Fölsch, W E Schmid. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. European journal of clinical investigation. vol 29. issue 7. 1999-08-16. PMID:10411667. |
glucagon-like peptide 1 (glp-1) stimulates insulin secretion and may improve glycaemic control in type 2 diabetes. |
1999-08-16 |
2023-08-12 |
rat |
| C C Tseng, X Y Zhang, M M Wolf. Effect of GIP and GLP-1 antagonists on insulin release in the rat. The American journal of physiology. vol 276. issue 6. 1999-07-29. PMID:10362617. |
effect of gip and glp-1 antagonists on insulin release in the rat. |
1999-07-29 |
2023-08-12 |
rat |
| C C Tseng, X Y Zhang, M M Wolf. Effect of GIP and GLP-1 antagonists on insulin release in the rat. The American journal of physiology. vol 276. issue 6. 1999-07-29. PMID:10362617. |
to examine their relative contribution to postprandial insulin release, a specific gip antagonist (antgip) and a glp-1 antagonist, exendin-(9-39)-nh2, were infused into rats after an intragastric glucose meal. |
1999-07-29 |
2023-08-12 |
rat |
| C C Tseng, X Y Zhang, M M Wolf. Effect of GIP and GLP-1 antagonists on insulin release in the rat. The American journal of physiology. vol 276. issue 6. 1999-07-29. PMID:10362617. |
the results of these studies suggest that gip and glp-1 may share a common mechanism in stimulating pancreatic insulin release. |
1999-07-29 |
2023-08-12 |
rat |
| U Plöckinger, J J Holst, D Messerschmidt, W Hopfenmüller, H J Quabb. Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects. European journal of endocrinology. vol 140. issue 6. 1999-07-28. PMID:10377503. |
to study the effect of octreotide on glucagon-like peptide (7-36) amide (glp-1) and insulin secretion in patients with pituitary tumors during preoperative treatment and in healthy subjects. |
1999-07-28 |
2023-08-12 |
human |
| L R Ranganath, J M Beety, L M Morga. Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 31. issue 4. 1999-07-01. PMID:10333081. |
inhibition of insulin, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity. |
1999-07-01 |
2023-08-12 |
human |
| L R Ranganath, J M Beety, L M Morga. Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 31. issue 4. 1999-07-01. PMID:10333081. |
this study examines the immediate effect of modulating postprandial insulin and insulinotropic hormone (glucose-dependent insulinotropic polypeptide, gip; glucagon-like peptide-1, glp-1) secretion on the activation of lipoprotein lipase (lpl) in six lean and six obese age-matched women. |
1999-07-01 |
2023-08-12 |
human |
| L R Ranganath, J M Beety, L M Morga. Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 31. issue 4. 1999-07-01. PMID:10333081. |
insulin, gip and glp-1 secretion post-carbohydrate was markedly reduced by octreotide in lean and obese subjects. |
1999-07-01 |
2023-08-12 |
human |
| L R Ranganath, J M Beety, L M Morga. Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 31. issue 4. 1999-07-01. PMID:10333081. |
inhibition of postprandial insulin, gip and glp-1 secretion acutely did not reduce post-heparin lpl activity either in lean or obese subjects. |
1999-07-01 |
2023-08-12 |
human |
| G G Holz, C A Leech, R S Heller, M Castonguay, J F Habene. cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). The Journal of biological chemistry. vol 274. issue 20. 1999-06-17. PMID:10318832. |
in vitro studies of pancreatic islets of langerhans demonstrated that glp-1 interacts with specific beta-cell g protein-coupled receptors, thereby facilitating insulin exocytosis by raising intracellular levels of camp and ca2+. |
1999-06-17 |
2023-08-12 |
mouse |
| E G Siegel, B Gallwitz, G Scharf, R Mentlein, C Morys-Wortmann, U R Fölsch, J Schrezenmeir, K Drescher, W E Schmid. Biological activity of GLP-1-analogues with N-terminal modifications. Regulatory peptides. vol 79. issue 2-3. 1999-05-28. PMID:10100921. |
glucagon-like peptide-1 (glp-1) stimulates insulin secretion and improves glycemic control in type 2 diabetes. |
1999-05-28 |
2023-08-12 |
Not clear |
| E G Siegel, B Gallwitz, G Scharf, R Mentlein, C Morys-Wortmann, U R Fölsch, J Schrezenmeir, K Drescher, W E Schmid. Biological activity of GLP-1-analogues with N-terminal modifications. Regulatory peptides. vol 79. issue 2-3. 1999-05-28. PMID:10100921. |
plasma glucose and insulin were monitored over 4 h. compared to native glp-1, analogues with an altered position 2 showed similar or increased potency and biological half-time. |
1999-05-28 |
2023-08-12 |
Not clear |
| H Sandhu, S R Wiesenthal, P E MacDonald, R H McCall, V Tchipashvili, S Rashid, M Satkunarajah, D M Irwin, Z Q Shi, P L Brubaker, M B Wheeler, M Vranic, S Efendic, A Giacc. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes. vol 48. issue 5. 1999-05-27. PMID:10331409. |
to determine whether glucagon-like peptide (glp)-1 increases insulin sensitivity in addition to stimulating insulin secretion, we studied totally depancreatized dogs to eliminate glp-1's incretin effect. |
1999-05-27 |
2023-08-12 |
Not clear |
| H Sandhu, S R Wiesenthal, P E MacDonald, R H McCall, V Tchipashvili, S Rashid, M Satkunarajah, D M Irwin, Z Q Shi, P L Brubaker, M B Wheeler, M Vranic, S Efendic, A Giacc. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes. vol 48. issue 5. 1999-05-27. PMID:10331409. |
glucose was clamped at this level for the remainder of the experiment, which included peripheral insulin infusion (high dose, 5.4 pmol x kg(-1) x min(-1), or low dose, 0.75 pmol x kg(-1) x min(-1)) with or without glp-1(7-36) amide (1.5 pmol x kg(-1) x min(-1)). |
1999-05-27 |
2023-08-12 |
Not clear |